IRadimed Corp

IRadimed Corp(IRMD)の株式分析

$86.380

-0.682 (-0.79%)終値時点

Loading chart…
High
86.858
Open
86.570
VWAP
86.16
Vol
113.02K
Mkt Cap
556.72M
Low
85.250
Amount
9.74M
EV/EBITDA, TTM
31.78

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories, disposables and services. Its MRidium 3870 MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium 3860+ MRI Compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to safely and predictably and other IV fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably on magnetic fields of over 30,000 gauss.

AI analysis of IRadimed Corp (IRMD)

hold

IRadimed Corp is currently not a strong buy due to its recent performance and technical indicators. The stock is priced at $87.07, with an RSI of 38.6 indicating it is in the oversold territory. The forward P/E ratio stands at 41.15, suggesting it may be overvalued compared to its earnings growth potential. The main risk is the declining gross margin, which fell to 74% from 78% year-over-year, indicating rising production costs that could affect profitability.

Analyst Ratings (2)

+14.61% upside
Buy
1 Buy
1 Hold
0 Sell
Current: 86.38
安値
98.00
平均
99.00
高値
100.00

Lake Street

2026-02-11

目標株価

$120

Buy

Roth Capital

2026-02-10

目標株価

$120

Buy

Roth Capital

2025-11-04

目標株価

$98

Buy

Lake Street

2025-11-03

目標株価

$100

Buy

Roth Capital

2025-11-03

目標株価

$98

Buy

バリュエーション指標

The current forward P/E ratio for IRadimed Corp (IRMD) is 41.15, compared to its 5-year average forward P/E of 36.63.

Forward P/E

Fair
5Y Average P/E
36.63
Current P/E
41.15
割高
44.92
割安
28.33

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
4.52
Current EV/EBITDA
31.78
割高
16.08
割安
-7.05

Forward P/S

Fair
5Y Average P/S
9.10
Current P/S
11.02
割高
11.12
割安
7.07

Alphio AI Price Scenarios for IRMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%IRMD

$56.90

シナリオ価格

B

Base

Base · 50%IRMD

$48.18

シナリオ価格

B

Bear

Bear · 25%IRMD

$42.24

シナリオ価格

Whales holding IRMD

C

Copeland Capital Management, LLC

+ HoldingIRMD

-8.71%

3M Return

イベントタイムライン

2026-05-01 (ET)

08:40:00

Company Reports Q1 Revenue of $21.98M, Beating Consensus

08:40:00

Sees Q2 Revenue of $20M-$21M for 2026

08:40:00

Company Reaffirms FY26 Revenue Guidance of $91M to $96M

2026-02-10 (ET)

16:30:00

Major Averages Mixed as Investors Await Jobs Report

12:20:00

Dow Jones Hits Record High, Major Averages Slightly Up

ニュース

IRMD FAQ — answered by Alphio AI

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories, disposables and services. Its MRidium 3870 MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium 3860+ MRI Compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to safely and predictably and other IV fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably on magnetic fields of over 30,000 gauss. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

IRadimed Corp is currently not a strong buy due to its recent performance and technical indicators. The stock is priced at $87.07, with an RSI of 38.6 indicating it is in the oversold territory. The forward P/E ratio stands at 41.15, suggesting it may be overvalued compared to its earnings growth potential. The main risk is the declining gross margin, which fell to 74% from 78% year-over-year, indicating rising production costs that could affect profitability.

2 analysts cover IRMD: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める